TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
VGX Pharmaceuticals Inc.
VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered with Electroporation Provides 100% Protection of Non-Human Primates
March 10th, 2009
VGX Pharmaceuticals Inc. (VGX), a leading developer of DNA vaccines and therapies for infectious diseases and cancer, announced preclinical results indicating that its avian influenza DNA vaccine delivered using intramuscular or intradermal electroporation provided 100% protection of non-human primates against the H5N1 avian influenza virus. The vaccine also provided protection against multiple unmatched avian influenza strains. The data was published in the Journal of Virology in a paper titled, “Electroporation of Synthetic DNA Antigens Offers Protection in Non-Human Primates Challenged with Highly Pathogenic Avian Influenza.” The results support advancing this DNA vaccine candidate into...
Source: TB & Outbreaks Week (2009-03-10)
|
